The Portuguese generic medicines market: A policy analysis

  • Steven Simoens
Keywords: Drugs, Generic, Reimbursement, Incentive, Drug Costs, Portugal

Abstract

Objectives: This study aims to conduct a descriptive analysis of the policy environment surrounding the generic medicines retail market in Portugal. The policy analysis focuses on supply-side measures (i.e. market access, pricing, reference-pricing and reimbursement of generic medicines) and demand-side measures (i.e. incentives for physicians to prescribe, for pharmacists to dispense and for patients to use generic medicines).

Methods: The policy analysis was based on an international literature review. Also, a simulation exercise was carried out to compute potential savings from substituting generic for originator medicines in Portugal using IMS Health data.

Results: Portugal has developed a successful generic medicines market by increasing reimbursement of generic medicines (until October 2005), by introducing a reference-pricing system, by encouraging physicians to prescribe by international non-proprietary name (INN), and by allowing generic substitution by pharmacists. However, the development of the generic medicines market has been hindered by the existence of copies, pricing regulation, certain features of the reference-pricing system, weak incentives for physicians to prescribe generic medicines and a financial disincentive for pharmacists to dispense generic medicines. Increased generic substitution would be expected to reduce public expenditure on originator medicines by 45%.

Conclusions: The development of the Portuguese generic medicines market has mainly been fuelled by supply-side measures. To support the further expansion of the market, policy makers need to strengthen demand-side measures inciting physicians to prescribe, pharmacists to dispense and patients to use generic medicines.

Downloads

Download data is not yet available.

References

1. Organisation for Economic Co-operation and Development (OECD). Health at a glance 2007: OECD indicators. Paris; OECD, 2007.

2. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official J EU. L 136/34-57.

3. European Generic Medicines Association. Basic notions of generics. Brussels; European Generic Medicines Association, 2008.

4. Simoens S, De Coster S. Sustaining generic medicines markets in Europe. J Generic Med. 2006;3:257-268.

5. IMS Health. Midas database. IMS Health; London, 2004.

6. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med. 2005;142(11):891-897.

7. Cox E, Behm A, Mager D, Miller S. Generic drug usage report. St. Louis; Express Scripts, 2004. Available at: http://www.express-scripts.com. Accessed September 17, 2008.

8. INFARMED. Market data. Lisbon; INFARMED, 2008. Available at: http://www.infarmed.pt/portal/page/portal/INFARMED (Accessed September 16, 2008).

9. European Generic Medicines Association. 2005 market review. The European generic pharmaceutical markets: price and reimbursement systems. Brussels; European Generic Medicines Association, 2005.

10. Directive 1989/105/EEC of 21st December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems. Official J EU. L 40/8-11.

11. European Generic Medicines Association. 2007 market review. The European generic pharmaceutical markets: price and reimbursement systems. Brussels; European Generic Medicines Association, 2007.

12. Barros PP, de Almeida Simoes J. Portugal: health system review. Health Systems in Transition. 2007;9:1-140.

13. Portela C, Pinto M. Reference pricing as a competition trigger on the Portuguese pharmaceutical market. Oral presentation at the 9th Conference of the Portuguese Association of Health Economics. Coimbra; November 22, 2005.

14. Pinto CG, Teixeira I. Pricing and reimbursement of pharmaceuticals in Portugal. Eur J Health Econ. 2002;3:267-270.

15. INFARMED. Estudo de Opinião sobre Medicamentos Genéricos (Study of the opinion about generic medicines). Lisbon; INFARMED, 2006. Available at: http://www.infarmed.pt/portal/page/portal/INFARMED (Accessed January 28, 2009).

16. INFARMED. Newsletter no. 19. Lisbon; INFARMED, 2006. Available at: http://www.infarmed.pt/infarmed_noticias/infarmed_noticias_01_02_2006.pdf (Accessed September 19, 2008).

17. Figueiras MJ, Marcelino D, Cortes MA. People's views on the level of agreement of generic medicines for different illnesses. Pharm World Sci. 2008;30(5):590-594.

18. Kanavos P, Taylor D. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings? Curr Med Res Opin. 2007;23(10):2467-2476.
Published
2009-06-16
How to Cite
1.
Simoens S. The Portuguese generic medicines market: A policy analysis. Pharm Pract (Granada) [Internet]. 2009Jun.16 [cited 2019Aug.18];7(2):74-0. Available from: https://pharmacypractice.org/journal/index.php/pp/article/view/163
Section
Original Research